FDA Pulls Biosimilar Analytics Guidance Amid Comments on Flexibility

The FDA withdrew its draft guidance on analytical studies of biosimilars Thursday and said it plans to issue an amended version that will give sponsors “appropriate flexibility.”
Source: Drug Industry Daily